Renal Transplantation Update

  1. RICHARD N. FINE, M.D.;
  2. PAUL I. TERASAKI, Ph.D.;
  3. ROBERT B. ETTENGER, M.D.;
  4. GABRIEL DANOVITCH, M.D.; and
  5. RICHARD M. EHRLICH, M.D.
  1. Los Angeles, California

    Abstract

    Various factors affect the outcome of renal transplants in humans. Matching for HLA-A, -B, and -DR histocompatibility antigens improves survival rates for renal allografts from first cadaver donors. Zero-HLA-A- and -B-antigen-mismatched grafts and two-HLA-DR-antigen-matched grafts do better, although results differ depending on the recipient's primary renal disease. Pretransplant third-party blood transfusions significantly improve survival rates of cadaver donor allografts. The mechanism of this beneficial effect has not been identified; however, blood transfusions probably do not "select out" high responders among potential recipients by stimulating the production of lymphocytotoxic antibodies. Cyclosporine has been heralded as a potent, nonspecific immunosuppressive agent that will significantly improve renal allograft survival rates. The selectivity of cyclosporine's effect on T lymphocytes is advantageous; however, its side effects, especially nephrotoxicity, may limit its usefulness. Attention to the potential surgical complications of renal transplantation can significantly reduce morbidity and mortality.

    Article and Author Information

    • ▸An edited summary of an Interdepartmental Conference arranged by the Department of Medicine of the UCLA School of Medicine; Los Angeles, California. Director of Conferences: William M. Pardridge, M.D.

    • ▸Authors who wish to cite a section of this conference and specifically indicate its author can use this example for the form of the reference:

      ETTENGER RB. Pretransplant blood transfusions and renal transplantation outcome, pp. 248-51. In: FINE RN, moderator. Renal transplantation update. Ann Intern Med. 1984;100:246-57.

    • Annette V. Terzian, UCLA School of Medicine, provided editorial assistance.

    • ▸Request for reprints should be addressed to Richard N. Fine, M.D.; Department of Pediatrics, Division of Pediatric Nephrology, UCLA School of Medicine; Los Angeles, CA 90024.

    | Table of Contents
    Most Read Most Read
    Most Commented Most Commented On
    Annals in the News Annals in the News
    Clinical Trials Clinical Trials
    Comparative Effectiveness Comparative Effectiveness
    Hospital Medicine Hospital Medicine
    • Advertisement
    • Advertisement